Login / Signup

Time for a lead-time definition? Author response to 'Why the length of recurrence free survival or "lead-times" can be misleading. Comment on: Callesen LB, Takacova T, Hamfjord J, et al. Circulating DNA in patients undergoing loco-regional treatment of colorectal cancer metastases: a systematic review and meta-analysis'.

Karen-Lise Garm SpindlerLouise Bach CallesenDirk Arnold
Published in: Therapeutic advances in medical oncology (2023)
Keyphrases
  • free survival
  • patients undergoing
  • circulating tumor
  • cell free
  • replacement therapy